American Journal of Obstetrics & Gynecology
Volume 204, Issue 1 , Pages 11-18, January 2011

Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia

  • John R. Lurain, MD

      Affiliations

    • Corresponding Author InformationReprints: John R. Lurain, MD, John I. Brewer Trophoblastic Disease Center, Northwestern University Feinberg School of Medicine, 250 E. Superior St., Suite 05-2168, Chicago, IL 60611

John I. Brewer Trophoblastic Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL

Received 17 June 2010; accepted 30 June 2010. published online 27 August 2010.

Gestational trophoblastic neoplasia (GTN) includes invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. The overall cure rate in treating these tumors is currently >90%. Thorough evaluation and staging allow selection of appropriate therapy that maximizes chances for cure while minimizing toxicity. Nonmetastatic (stage I) and low-risk metastatic (stages II and III, score <7) GTN can be treated with single-agent chemotherapy resulting in a survival rate approaching 100%. High-risk GTN (stages II-IV, score ≥7) requires initial multiagent chemotherapy with or without adjuvant radiation and surgery to achieve a survival rate of 80-90%.

Key words: chemotherapy, choriocarcinoma, gestational trophoblastic disease, gestational trophoblastic neoplasia

 

PII: S0002-9378(10)00852-5

doi:10.1016/j.ajog.2010.06.072

American Journal of Obstetrics & Gynecology
Volume 204, Issue 1 , Pages 11-18, January 2011